COVID19NCT04394000
Impact of an Intensified Thromboprofylaxis Protocol in COVID-19
An observational study of COVID19 and Thromboembolism, run by Jessa Hospital at 1 site in Belgium.
Trial summary
The aim of this study is to investigate and compare the mortality, the incidence of DVT and the incidence of kidney and liver failure in patients admitted to the ICU before and after the implementation of an intensified thromboprofylaxis protocol on 31st of March 2020. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- COVID19, Thromboembolism
- What is being tested?
- thromboprofylaxis protocol and standard protocol
- How many people
- 72 participants
- Where
- 1 siteBelgium
- Study dates
- 4 May 2020to 15 May 2020
- How long will I take part?
- 1 Month
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: All adult COVID19+ patients admitted to the ICU from 13th of March until 20th of April 2020.
Who may be able to join
- All adult COVID19+ patients admitted to the ICU from 13th of March until 20th of April 2020.
Who cannot join
- Patients younger than 18 years old.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Impact of Implementation of an Intensified Thromboprofylaxis Protocol in in Critically Ill ICU Patients With COVID-19: a Longitudinal Controlled Before-after Study
The aim of this study is to investigate and compare the mortality, the incidence of DVT and the incidence of kidney and liver failure in patients admitted to the ICU before and after the implementation of an intensified thromboprofylaxis protocol on 31st of March 2020. Patients in the before group are admitted at the ICU from 13/3/2020-30/3/2020 and patients in the after group are admitted to the ICU from 31/3 until 20/4/2020.
Read the detailed description
Background Patients admitted to the Intensive Care Unit (ICU) are known to be at risk for thrombo-embolic events. Virchow's triad describes the major risk factors in three categories: venous stasis, vessel injury and activation of blood coagulation. A prolonged mechanical ventilation together with the hemodynamic effects of this ventilation with a high positive and expiratory pressure (PEEP), the presence of central venous catheters, the immobilization of these patients and the presence of obesity or other comorbidities can attribute to the occurrence of a deep venous thrombosis (DVT) in patients admitted at ICU. The incidence of DVT during ICU stay has been reported between 5 and 15%.
On the 13th of March, the first COVID-19 patient was admitted at the ICU at the Jessa Hospital. Within a few days, the admissions at our COVID-19 unit grew exponential. In these difficult time, research concerning COVID-19 has been performed indicating the COVID-19 virus induces a hyper-inflammatory state. It has been suggested that systemic inflammation induces endothelial injury. This will activate the coagulation cascade and impair fibrinolysis with disruption of endothelial barrier, and loss of physiologic antithrombotic factors which may elevated the risk for DVTs significantly. Up to now, there is still no causal treatment for COVID-19. The current management of COVID-19 is mainly supportive i.e. a prolonged inflammatory status and a prolonged risk for VTE.
We have shown in a previous cross sectional study that the prevalence of deep venous thrombosis (DVT) in critically ill ICU patients with COVID-19 treated with a prophylactic dose of low molecular weight heparin (LMWH) is more than 60% (submitted manuscript). Consequently, the risk of VTE complications in this patient group is very high. In the light of these findings, an intensified thromboprofylaxis protocol was applied in critically ill ICU patients with COVID-19 at our ICU units since 31st of March 2020.
Aim The aim of this study is to investigate and compare the mortality, the incidence of DVT and the incidence of kidney and liver failure in patients admitted to the ICU before and after the implementation of an intensified thromboprofylaxis protocol on 31st of March 2020. Patients in the before group are admitted at the ICU from 13/3/2020-30/3/2020 and patients in the after group are admitted to the ICU from 31/3 until 20/4/2020.
Design This is a retrospective, longitudinal, before-after controlled study investigating the mortality, the incidence of DVT and the incidence of kidney and liver failure in COVID-19 patients admitted to the ICU before and after the implementation of an intensified thromboprofylaxis protocol.
Outcome measures The primary endpoint of this retrospective study is to investigate the mortality in critically ill ICU patients before and after the implementation of the intensified thromboprofylaxis protocol in our hospital.
Secondary endpoints are the incidence of DVTs with the number and locations of these thromboses, the incidence of kidney failure and the incidence of liver failure in COVID-19 patients admitted to the ICU before and after the implementation of the thromboprofylaxis protocol.
Additional data collection
Additional collected parameters are listed below and are collected as a standard-of-care in our hospital:
- Demographics: i.e age, gender, BMI, Apache II score (to predict mortality)
- Comorbidities: smoking, obesity, hypertension, diabetes, cardiovascular disease, respiratory disease, malignancies, renal failure (AKI), liver failure, gastrointestinal disease, neurological conditions, mental state, other
- Symptoms at the time of admission to ICU: i.e fever, body temperature, dyspnoea, headache, diarrhea etc…
- Laboratory results of all standard parameters measured
- Treatment: antiviral agents, antibiotics, etc…
- Complications: shock, heart failure, sepsis, stroke, etc…
- Ventilation: method, PEEP, FiO2, P/F ratio ..
- SOFA score (Sequential Organ Failure Assessment)
- Radiological findings: pneumonia, ground-glass opacity..
- Conditions
- COVID19, Thromboembolism
- Being tested
- thromboprofylaxis protocol, standard protocol
- Medical subject headings
- COVID-19, Thromboembolism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
thromboprofylaxis protocolOther
This individualised protocol contains three cornerstones: an increase in dosage of prophylactic LMWH close to therapeutic doses, introduction of routine venous ultrasonography and daily measurements of plasma anti-factor Xa activity
standard protocolOther
This protocol contains a routine low dose pharmacological venous thromboembolism (VTE) prophylaxis with LMWH
| Study group | Role | What they receive |
|---|---|---|
| Before or control group | All patients admitted to ICU from March 13th 2020 until March 30th 2020 received routine low dose pharmacological VTE prophylaxis Receives: Other: standard protocol | |
| After or intervention group | On March 31th 2020 an individualised, more aggressive thromboprophylaxis protocol was implemented. This individualised protocol contains three cornerstones: an increase in dosage of prophylactic LMWH close to therapeutic doses, introduction of routine venous ultrasonography and daily measurements of plasma anti-factor Xa activity Receives: Other: thromboprofylaxis protocol |
What is being measured
The primary outcome is the main question the study is designed to answer.
2 week mortality
mortality was assessed in all COVID 19 patients admitted to the ICU
Measured: 2 weeks after admission at ICU
Secondary outcomes (12)
incidence of venous thromboembolism
the incidence of venous thromboembolism was evaluated in all COVID 19 patients admitted to the ICU
Measured: during ICU stay up till 3th of May 2020
1 week mortality
mortality was assessed in all COVID 19 patients admitted to the ICU
Measured: 1 week after admission at ICU
3 week mortality
mortality was assessed in all COVID 19 patients admitted to the ICU
Measured: 3 weeks after admission at ICU
1 month mortality
mortality was assessed in all COVID 19 patients admitted to the ICU
Measured: 1 month after admission at ICU
incidence of kidney failure
incidence of acute kidney failure in all COVID 19 patients admitted to the ICU
Measured: during ICU stay up till 3th of May 2020
incidence of continuous renal replacement therapy (CRRT)
incidence of continuous renal replacement therapy (CRRT) in all COVID 19 patients admitted to the ICU
Measured: during ICU stay up till 3th of May 2020
lowest PaO2/FiO2 (P/F) ratio
evaluation of the lowest P/F ratio in all COVID 19 patients admitted to the ICU
Measured: during ICU stay up till 3th of May 2020
highest Sequential Organ Failure Assessment (SOFA) score
evaluation of the highest SOFA score in all COVID 19 patients admitted to the ICU
Measured: during ICU stay up till 3th of May 2020
length of stay
evaluation of the length of stay in ICU and hospital of all COVID 19 patients admitted to the ICU
Measured: during ICU and hospital stay up till 3th of May 2020
highest bilirubin
evaluation of the highest bilirubine level in all COVID 19 patients admitted to the ICU
Measured: during ICU stay up till 3th of May 2020
highest ( AST
evaluation of the highest AST level in all COVID 19 patients admitted to the ICU
Measured: during ICU stay up till 3th of May 2020
highest Aspartaat-Amino-Transferase (ALT)
evaluation of the highest ALT level in all COVID 19 patients admitted to the ICU
Measured: during ICU stay up till 3th of May 2020
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 May 2020
- Study start4 May 2020
- Primary completion15 May 2020
- Study completion15 May 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for COVID19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 72 participants (actual)
- Target duration
- 1 Month
Sponsor and investigators
- Lead sponsor
- Jessa Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04394000
- Sponsor's protocol ID
- Jessa_20.48
- Status last verified
- May 2020
- First submitted
- 16 May 2020
- Last updated
- 19 May 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Stessel B, Vanvuchelen C, Bruckers L, Geebelen L, Callebaut I, Vandenbrande J, Pellens B, Van Tornout M, Ory JP, van Halem K, Messiaen P, Herbots L, Ramaekers D, Dubois J. Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: A longitudinal controlled before-after study. Thromb Res. 2020 Oct;194:209-215. doi: 10.1016/j.thromres.2020.07.038. Epub 2020 Jul 22.
PubMed 32788120
Study at a glance
From the registry record, last updated by the sponsor on 19 May 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Implementation of an Intensified Thromboprofylaxis Protocol in in Critically Ill ICU Patients With COVID-19: a Longitudinal Controlled Before-after Study
- ClinicalTrials.gov ID
- NCT04394000
- Acronym / sponsor ID
- Jessa_20.48
- Conditions
- COVID19, Thromboembolism
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 72 participants (actual)
- Lead sponsor
- Jessa HospitalUniversity, hospital or other
- Study start
- 4 May 2020 (actual)
- Primary completion
- 15 May 2020 (actual)
- Study completion
- 15 May 2020 (actual)
- First posted
- 19 May 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to investigate and compare the mortality, the incidence of DVT and the incidence of kidney and liver failure in patients admitted to the ICU before and after the implementation of an intensified thromboprofylaxis protocol on 31st of March 2020. Patients in the before group are admitted at the ICU from 13/3/2020-30/3/2020 and patients in the after group are admitted to the ICU from 31/3 until 20/4/2020.
Detailed description
Background Patients admitted to the Intensive Care Unit (ICU) are known to be at risk for thrombo-embolic events. Virchow's triad describes the major risk factors in three categories: venous stasis, vessel injury and activation of blood coagulation. A prolonged mechanical ventilation together with the hemodynamic effects of this ventilation with a high positive and expiratory pressure (PEEP), the presence of central venous catheters, the immobilization of these patients and the presence of obesity or other comorbidities can attribute to the occurrence of a deep venous thrombosis (DVT) in patients admitted at ICU. The incidence of DVT during ICU stay has been reported between 5 and 15%.
On the 13th of March, the first COVID-19 patient was admitted at the ICU at the Jessa Hospital. Within a few days, the admissions at our COVID-19 unit grew exponential. In these difficult time, research concerning COVID-19 has been performed indicating the COVID-19 virus induces a hyper-inflammatory state. It has been suggested that systemic inflammation induces endothelial injury. This will activate the coagulation cascade and impair fibrinolysis with disruption of endothelial barrier, and loss of physiologic antithrombotic factors which may elevated the risk for DVTs significantly. Up to now, there is still no causal treatment for COVID-19. The current management of COVID-19 is mainly supportive i.e. a prolonged inflammatory status and a prolonged risk for VTE.
We have shown in a previous cross sectional study that the prevalence of deep venous thrombosis (DVT) in critically ill ICU patients with COVID-19 treated with a prophylactic dose of low molecular weight heparin (LMWH) is more than 60% (submitted manuscript). Consequently, the risk of VTE complications in this patient group is very high. In the light of these findings, an intensified thromboprofylaxis protocol was applied in critically ill ICU patients with COVID-19 at our ICU units since 31st of March 2020.
Aim The aim of this study is to investigate and compare the mortality, the incidence of DVT and the incidence of kidney and liver failure in patients admitted to the ICU before and after the implementation of an intensified thromboprofylaxis protocol on 31st of March 2020. Patients in the before group are admitted at the ICU from 13/3/2020-30/3/2020 and patients in the after group are admitted to the ICU from 31/3 until 20/4/2020.
Design This is a retrospective, longitudinal, before-after controlled study investigating the mortality, the incidence of DVT and the incidence of kidney and liver failure in COVID-19 patients admitted to the ICU before and after the implementation of an intensified thromboprofylaxis protocol.
Outcome measures The primary endpoint of this retrospective study is to investigate the mortality in critically ill ICU patients before and after the implementation of the intensified thromboprofylaxis protocol in our hospital.
Secondary endpoints are the incidence of DVTs with the number and locations of these thromboses, the incidence of kidney failure and the incidence of liver failure in COVID-19 patients admitted to the ICU before and after the implementation of the thromboprofylaxis protocol.
Additional data collection
Additional collected parameters are listed below and are collected as a standard-of-care in our hospital:
- Demographics: i.e age, gender, BMI, Apache II score (to predict mortality)
- Comorbidities: smoking, obesity, hypertension, diabetes, cardiovascular disease, respiratory disease, malignancies, renal failure (AKI), liver failure, gastrointestinal disease, neurological conditions, mental state, other
- Symptoms at the time of admission to ICU: i.e fever, body temperature, dyspnoea, headache, diarrhea etc…
- Laboratory results of all standard parameters measured
- Treatment: antiviral agents, antibiotics, etc…
- Complications: shock, heart failure, sepsis, stroke, etc…
- Ventilation: method, PEEP, FiO2, P/F ratio ..
- SOFA score (Sequential Organ Failure Assessment)
- Radiological findings: pneumonia, ground-glass opacity..
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Target follow-up
- 1 Month
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Before or control group | – | Other: standard protocolAll patients admitted to ICU from March 13th 2020 until March 30th 2020 received routine low dose pharmacological VTE prophylaxis |
| After or intervention group | – | Other: thromboprofylaxis protocolOn March 31th 2020 an individualised, more aggressive thromboprophylaxis protocol was implemented. This individualised protocol contains three cornerstones: an increase in dosage of prophylactic LMWH close to therapeutic doses, introduction of routine venous ultrasonography and daily measurements of plasma anti-factor Xa activity |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- All adult COVID19+ patients admitted to the ICU from 13th of March until 20th of April 2020.
Key inclusion criteria (1 listed)
- All adult COVID19+ patients admitted to the ICU from 13th of March until 20th of April 2020.
Key exclusion criteria (1 listed)
- Patients younger than 18 years old.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| thromboprofylaxis protocolThis individualised protocol contains three cornerstones: an increase in dosage of prophylactic LMWH close to therapeutic doses, introduction of routine venous ultrasonography and daily measurements of plasma anti-factor Xa activity | Other | After or intervention group |
| standard protocolThis protocol contains a routine low dose pharmacological venous thromboembolism (VTE) prophylaxis with LMWH | Other | Before or control group |
Primary outcome
2 week mortality
Time frame: 2 weeks after admission at ICU
mortality was assessed in all COVID 19 patients admitted to the ICU
12 secondary outcomes
incidence of venous thromboembolism
Time frame: during ICU stay up till 3th of May 2020
1 week mortality
Time frame: 1 week after admission at ICU
3 week mortality
Time frame: 3 weeks after admission at ICU
1 month mortality
Time frame: 1 month after admission at ICU
incidence of kidney failure
Time frame: during ICU stay up till 3th of May 2020
incidence of continuous renal replacement therapy (CRRT)
Time frame: during ICU stay up till 3th of May 2020
lowest PaO2/FiO2 (P/F) ratio
Time frame: during ICU stay up till 3th of May 2020
highest Sequential Organ Failure Assessment (SOFA) score
Time frame: during ICU stay up till 3th of May 2020
length of stay
Time frame: during ICU and hospital stay up till 3th of May 2020
highest bilirubin
Time frame: during ICU stay up till 3th of May 2020
highest ( AST
Time frame: during ICU stay up till 3th of May 2020
highest Aspartaat-Amino-Transferase (ALT)
Time frame: during ICU stay up till 3th of May 2020
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 May 2020.
- Derived from this study: PubMed 32788120Stessel B, Vanvuchelen C, Bruckers L, Geebelen L, Callebaut I, Vandenbrande J, Pellens B, Van Tornout M, Ory JP, van Halem K, Messiaen P, Herbots L, Ramaekers D, Dubois J. Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: A longitudinal controlled before-after study. Thromb Res. 2020 Oct;194:209-215. doi: 10.1016/j.thromres.2020.07.038. Epub 2020 Jul 22.
- Individual participant dataSharing planned: No
Related trials for COVID19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of COVID19 and Thromboembolism, run by Jessa Hospital at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 May 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
2 week mortality (time frame: 2 weeks after admission at ICU). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04394000, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 May 2020.